Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.

Burstein HJ, Griggs JJ.

J Clin Oncol. 2012 Mar 1;30(7):684-6. doi: 10.1200/JCO.2011.40.1455. Epub 2012 Jan 23. No abstract available.

PMID:
22271478
2.

Recent advances in aromatase inhibitor therapy for breast cancer.

Assikis VJ, Buzdar A.

Semin Oncol. 2002 Jun;29(3 Suppl 11):120-8. Review.

PMID:
12138406
3.

Current developments in hormonal therapy of breast cancer.

Buzdar AU.

Clin Breast Cancer. 2004 Sep;5 Suppl 1:S4-5. Review. No abstract available.

PMID:
15347432
4.

[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].

Lindberg H, Nielsen DL, Tuxen M, Kamby C.

Ugeskr Laeger. 2007 Sep 10;169(37):3096-100. Review. Danish.

PMID:
17877958
5.

[Advancement in endocrine therapy for breast cancer].

Yang MT, Lian ZQ.

Ai Zheng. 2007 Apr;26(4):440-4. Review. Chinese.

PMID:
17430670
6.

Nonsteroidal and steroidal aromatase inhibitors in breast cancer.

Hamilton A, Volm M.

Oncology (Williston Park). 2001 Aug;15(8):965-72; discussion 972, 977-9. Review.

7.

[Endocrine therapy of causation: role of aromatase inhibitors in breast cancer].

Longo F, Mansueto G.

Tumori. 2003 Nov-Dec;89(6):21-8. Review. Italian. No abstract available.

PMID:
14870836
8.

Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?

Freedman OC, Verma S, Clemons MJ.

Cancer Treat Rev. 2005 Feb;31(1):1-17. Epub 2004 Nov 18. Review.

PMID:
15707700
9.

Aromatase inhibitors and breast cancer: time for a change?

Fentiman IS.

Int J Clin Pract. 2004 Dec;58(12):1152-8. Review.

PMID:
15646413
10.
11.

The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.

Herold CI, Blackwell KL.

Breast. 2008 Jan;17 Suppl 1:S15-24. doi: 10.1016/S0960-9776(08)70004-3. Review.

PMID:
18279763
12.

[Aromatase inhibitors in adjuvant setting in breast cancer].

Spano JP, Khayat D, Delozier T.

Bull Cancer. 2004 Dec 1;91 Suppl 4:S239-43. Review. French.

13.

Unravelling exemestane: From biology to clinical prospects.

Sobral AF, Amaral C, Correia-da-Silva G, Teixeira N.

J Steroid Biochem Mol Biol. 2016 Oct;163:1-11. doi: 10.1016/j.jsbmb.2016.03.019. Epub 2016 Mar 15. Review.

PMID:
26992705
14.

[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].

van Nes JG, Seynaeve C, van de Velde CJ, Nortier JW.

Ned Tijdschr Geneeskd. 2006 Dec 30;150(52):2863-9. Review. Dutch.

PMID:
17319217
16.

Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.

Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R, Maass N, Noguchi S, Robidoux A, Verma S, Hadji P.

Breast. 2009 Aug;18 Suppl 2:S1-11. doi: 10.1016/S0960-9776(09)70002-5. Review. No abstract available.

PMID:
19712865
17.

Breast cancer (metastatic).

Stebbing J, Crane J, Gaya A.

Clin Evid. 2006 Jun;(15):2331-59. Review. No abstract available.

PMID:
16973089
18.
19.

[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].

de Cremoux P, Diéras V, Poupon MF, Magdelénat H, Sigal-Zafrani B, Fourquet A, Pierga JY.

Bull Cancer. 2004 Dec;91(12):917-27. Review. French.

20.

Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.

Henderson IC.

Semin Oncol. 2004 Dec;31(6 Suppl 12):31-4. Review.

PMID:
15719599

Supplemental Content

Support Center